" class="no-js "lang="en-US"> Clay Wilemon - Medtech Alert
Friday, January 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Clay Wilemon

Clay Wilemon

About Clay Wilemon

Clay Wilemon currently serves as President and Chief Commercial Officer at APATICS™ and Chairman of This Stone, Inc. He has extensive healthcare marketing experience including helping medical device, biotech, diagnostics, pharmaceutical, and healthcare services companies launch over 500 new medical brands.

Clay is a graduate of Vanderbilt University. He has also been a co-founder and director in two medical device companies and holds a patent in musculoskeletal surgery.

In addition, Clay is a partner in the Visionary Venture Fund and an investor in medical technology and information technology companies. He also serves on the Board of Directors of Octane, a technology focused economic development organization in Southern California.